Outcrop Silver & Gold Corporation press release

Today's Research Reports on GLG Life Tech Corp., Trillium Therapeutics Inc., BELLUS Health Inc. and Acerus Pharmaceuticals Corporation

2017-08-18

TSXV - TSX Venture Exchange · Silver · Gold · Copper · Canada

NEW YORK, NY / ACCESSWIRE / August 18, 2017 /Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.comand get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

GLG Life Tech Corp. https://ub.rdinvesting.com/news/?ticker=GLG-TO

Trillium Therapeutics Inc. https://ub.rdinvesting.com/news/?ticker=TRIL-TO

BELLUS Health Inc. https://ub.rdinvesting.com/news/?ticker=BLU-TO

Acerus Pharmaceuticals Corporation https://ub.rdinvesting.com/news/?ticker=ASP-TO

GLG Life Tech Corp.'s stock had no change Thursday, to close the day at $0.56. The stock recorded a trading volume of 1,600 shares, which was below its three months average volume of 11,179 shares. In the last year GLG Life Tech Corp.'s shares have traded in a range of 0.19 - 0.57. The share price has gained 194.74% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.49 is greater than its 200-day moving average of $0.40. Shares of GLG Life Tech have gained approximately 138.3 percent year-to-date.

Access RDI'sGLG Life Tech Corp. Research Report at: https://ub.rdinvesting.com/news/?ticker=GLG-TO

On Thursday, shares in Trillium Therapeutics Inc. recorded a trading volume of 1,325 shares, which was below the three months average volume of 3,960 shares. The stock ended the day flat at 5.65. The stock is currently trading 75.94% below its 52 week high with a 52 week trading range of 5.26 - 23.48.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $5.78 is below its 200-day moving average of $7.22. Shares of Trillium Therapeutics have fallen approximately 25.76 percent year-to-date.

Access RDI'sTrillium Therapeutics Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=TRIL-TO

BELLUS Health Inc.'s stock moved 2.67% higher Thursday, to close the day at $0.39. The stock recorded a trading volume of 32,710 shares, which was below its three months average volume of 191,708 shares. In the last year BELLUS Health Inc.'s shares have traded in a range of 0.21 - 0.55. The share price has gained 83.33% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.39 is greater than its 200-day moving average of $0.33. Shares of BELLUS Health Inc. are trading at a Price to Earnings ratio of 96.25. Shares of BELLUS Health have gained approximately 32.76 percent year-to-date.

Access RDI'sBELLUS Health Inc. Research Report at: https://ub.rdinvesting.com/news/?ticker=BLU-TO

On Thursday, shares in Acerus Pharmaceuticals Corporation recorded a trading volume of 239,300 shares, which was above the three months average volume of 100,841 shares. The stock ended the day 4.55% lower at 0.10. The stock is currently trading 58.00% below its 52 week high with a 52 week trading range of 0.10 - 0.25.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.12 is below its 200-day moving average of $0.12. Shares of Acerus Pharmaceuticals Corporation have fallen approximately 22.22 percent year-to-date.

Access RDI'sAcerus Pharmaceuticals Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=ASP-TO

Our Actionable Research on GLG Life Tech Corp. (TSX:GLG.TO), Trillium Therapeutics Inc. (TSX:TRIL.TO), BELLUS Health Inc. (TSX:BLU.TO) and Acerus Pharmaceuticals Corporation (TSX:ASP.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com